Antibiotic resistance test for gonorrhea gets FDA breakthrough nod
FDA granted a breakthrough designation to Australia-based SpeeDx to expedite the path to U.S. clearance for a molecular test that detects both N. gonorrhea and a patient’s susceptibility or resistance to the antibiotic ciprofloxacin.
Results from the ResistancePlus GC test can be used to determine whether patients can be treated with ciprofloxacin rather than ceftriaxone, the current front-line treatment for gonorrhea.
There have been reports in the United Kingdom and Australia of resistance to ceftriaxone, an antibiotic used to treat many kinds of bacterial infections, including organisms that are resistant to other antibiotics.
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
 |
BD |
AMR NEWS
Your Biweekly Source for Global AMR Insights!
Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.
Don’t miss out on staying ahead in the global AMR movement—subscribe now!